OncologyTube Professional - Patients Click Here
MediComOncology
1,311 video views
Loading........
Description: The utilization of interim positron emission tomography (PET) imaging to guide therapeutic decisions has the potential to further individualize therapy, avoid unnecessary treatment and associated toxi...
19:35
The utilization of interim positron emission tomography (PET) imaging to guide therapeutic decisions has the potential to further individualize therapy, avoid unnecessary treatment and associated toxicity, and optimize outcomes for patients with Hodgkin lymphoma (HL). In this activity, participants ...
by:MediComOncology | 66 views
30:45
Presented by Aziz Nazha, MD. Acute myeloid leukemia (AML) is generally a hematologic malignancy of older adults, with approximately 60% of newly diagnosed AML patients being 60 or older. Older patients pose unique therapeutic challenges that have been largely unmet to date. This activity will review...
by:MediComOncology | 165 views
15:09
Presented by Ehab Atallah, MD. There is a significant unmet need in existing treatment paradigms for patients with acute myeloid leukemia (AML) due to poor survival and intolerability to cytotoxic chemotherapy, especially for a generally older patient population. Hypomethylating agents (HMAs) have d...
by:MediComOncology | 136 views
27:26
Presented by Guillermo Garcia-Manero, MD. In this video, Dr. Garcia-Manero presents four patient cases related to the investigational therapies discussed previously. The cases will focus on clinical pearls gained from clinical trial experience to help providers understand the practical application of these novel therapies in the real-world setting.
by:MediComOncology | 307 views
30:32
Presented by Jeffrey E. Lancet, MD. In this video, Dr. Lancet presents key safety and efficacy data on a number of promising investigational therapies being studied in AML, while sharing clinical pearls discovered through clinical trial experience. In addition, he will raise awareness for pertinent clinical trials currently recruiting patients to e...
by:MediComOncology | 203 views
19:43
Presented by Richard Stone, MD. In this video, Dr. Stone describes the existing treatment paradigms for patients with AML, sharing an overview of the advantages and disadvantages of currently available therapy. In addition, he will describe the unmet need that exist based upon patient-, disease-, and treatment-relat​ed factors, which are driving cli...
by:MediComOncology | 190 views
23:28
Presented by Elli Papaemmanuil, PhD. In this video, Dr. Papaemmanuil explains the role of molecular abnormalities in AML oncogenesis, including mutations in DNA methyltransfera​se (DNMT), isocitrate dehydrogenase 1 and 2 (IDH1/2), and FMS-like tyrosine kinase 3 (FLT3). In addition, she will describe the rationale for targeting these molecular abnorm...
by:MediComOncology | 244 views

About MediComOncology
Description: MediCom Oncology is comprehensive educational resource for community-based and academic healthcare practitioners who diagnose, treat, and manage patients with multiple myeloma, myelodysplastic syndromes, pancreatic cancer, Hodgkin lymphoma, and acute myeloid leukemia. Managed by MediCom Worldwide, Inc., an accredited provider of continuing education for physicians, pharmacists, and nurses.

Links
Channel Url:

Website:


Other Links: